Vancomycin: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: ==Adverse effects== ===Thrombocytopenia=== Vancomycin may cause immune thrombocytopenia.<ref name="pmid17329697">{{cite journal |author=Von Drygalski A, Curtis BR, Bougie DW, ''et al''...) |
imported>Robert Badgett |
||
| Line 4: | Line 4: | ||
==Acute kidney injury== | ==Acute kidney injury== | ||
Vancomycin is associated with [[acute kidney injury]] if trough levels are above 15 microg/mL.<ref name="pmid17060545">{{cite journal |author=Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A |title=High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity |journal=Arch. Intern. Med. |volume=166 |issue=19 |pages=2138–44 |year=2006 |pmid=17060545 |doi=10.1001/archinte.166.19.2138}}</ref> To avoid this, the blood levels of vancomycin should be monitored.<ref name="pmid12808304">{{cite journal |author=Iwamoto T, Kagawa Y, Kojima M |title=Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin |journal=Biol. Pharm. Bull. |volume=26 |issue=6 |pages=876–9 |year=2003 |pmid=12808304 |doi=|url=http://www.jstage.jst.go.jp/article/bpb/26/6/876/_pdf}}</ref> | Vancomycin is associated with [[acute kidney injury]] if trough levels are above 15 microg/mL.<ref name="pmid17060545">{{cite journal |author=Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A |title=High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity |journal=Arch. Intern. Med. |volume=166 |issue=19 |pages=2138–44 |year=2006 |pmid=17060545 |doi=10.1001/archinte.166.19.2138}}</ref> To avoid this, the blood levels of vancomycin should be monitored.<ref name="pmid7696720">{{cite journal |author=Welty TE, Copa AK |title=Impact of vancomycin therapeutic drug monitoring on patient care |journal=Ann Pharmacother |volume=28 |issue=12 |pages=1335–9 |year=1994 |pmid=7696720 |doi=}}</ref><ref name="pmid12808304">{{cite journal |author=Iwamoto T, Kagawa Y, Kojima M |title=Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin |journal=Biol. Pharm. Bull. |volume=26 |issue=6 |pages=876–9 |year=2003 |pmid=12808304 |doi=|url=http://www.jstage.jst.go.jp/article/bpb/26/6/876/_pdf}}</ref> | ||
==References== | ==References== | ||
Revision as of 11:56, 6 January 2008
Adverse effects
Thrombocytopenia
Vancomycin may cause immune thrombocytopenia.[1]
Acute kidney injury
Vancomycin is associated with acute kidney injury if trough levels are above 15 microg/mL.[2] To avoid this, the blood levels of vancomycin should be monitored.[3][4]
References
- ↑ Von Drygalski A, Curtis BR, Bougie DW, et al (2007). "Vancomycin-induced immune thrombocytopenia". N. Engl. J. Med. 356 (9): 904–10. DOI:10.1056/NEJMoa065066. PMID 17329697. Research Blogging.
- ↑ Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006). "High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity". Arch. Intern. Med. 166 (19): 2138–44. DOI:10.1001/archinte.166.19.2138. PMID 17060545. Research Blogging.
- ↑ Welty TE, Copa AK (1994). "Impact of vancomycin therapeutic drug monitoring on patient care". Ann Pharmacother 28 (12): 1335–9. PMID 7696720. [e]
- ↑ Iwamoto T, Kagawa Y, Kojima M (2003). "Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin". Biol. Pharm. Bull. 26 (6): 876–9. PMID 12808304. [e]